@entity342 deprivation therapy (ADT) for @entity263 is now used in earlier disease stages and as adjuvant treatment. Recognizing and reducing the @entity137 of this therapy, including worsened lipid levels and @entity65 ( @entity65 ) risks, has become an important clinical concern. Oral @entity172 therapy induces @entity6126 and mitigates many side effects of ADT, but has a high @entity715 risk. Transdermal @entity172 therapy ( @entity5981 ) has a lower @entity715 risk than oral @entity172 and may improve @entity65 risk compared with ADT. This prospective pilot study of 18 @entity1 with @entity342 -independent @entity263 receiving ADT measured effects of @entity5981 on lipid and inflammatory @entity65 risk factors before and after 8 weeks of @entity5981 ( @entity53 0.6 mg/day). During treatment, @entity53 levels rose 17-fold; total @entity165 , LDL @entity165 , and @entity755 levels decreased. @entity9477 @entity165 increased, with no changes in @entity412 or VLDL @entity165 levels. Dense LDL @entity165 decreased and LDL buoyancy increased in association with a decrease in HL activity. Highly sensitive @entity1851 levels and other inflammatory markers did not worsen. Compared with ADT, short-term @entity5981 therapy of @entity263 improves lipid levels without deterioration of @entity65 -associated inflammatory markers and may, on longer-term follow-up, improve @entity65 and mortality rates.

Effects of transdermal @entity172 on levels of lipids, lipase activity, and inflammatory markers in XXXX with @entity263 .

@entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity1 :: ('9606', 'Species') :: ['men'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol'] @entity755 :: ('338', 'Gene') :: ['apolipoprotein B'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity5981 :: ('MESH:D003632', 'Chemical') :: ['TDE'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['Androgen', 'androgen'] @entity6126 :: ('MESH:D007006', 'Disease') :: ['hypogonadism'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis'] @entity65 :: ('MESH:D002318', 'Disease') :: ['CVD', 'cardiovascular disease'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol'] @entity9477 :: ('57338', 'Gene') :: ['HDL2']
@entity1 :: (9606,Species) :: ['men']
